Purple Biotech Ltd.

Purple Biotech Ltd. is a clinical-stage biotechnology company headquartered in Rehovot, Israel, dedicated to developing first-in-class oncology therapies. The company's core mission is to overcome tumor immune evasion and drug resistance, aiming to improve treatment outcomes for cancer patients.

The company's pipeline includes the CAPTN-3 platform, CM24, and NT219. CAPTN-3 is a platform of masked tri-specific antibodies designed to target tumor-associated antigens while engaging both T cells and NK cells, with lead candidates IM1240 and IM1305 currently in preclinical development. CM24 is a humanized monoclonal antibody targeting CEACAM1, an immune checkpoint protein, which is being evaluated in a Phase 2 trial for metastatic pancreatic cancer in collaboration with Bristol Myers Squibb. NT219 is a novel small molecule dual inhibitor targeting IRS1/2 and STAT3, advancing in a Phase 1-2a trial for various solid tumors, including a Phase 2 study for recurrent/metastatic squamous cell carcinoma of the head and neck.

Gil Efron, appointed CEO in July 2022, is slated to step down in August 2026 for health reasons, transitioning to lead corporate development while remaining on the Board, with a search for a new CEO underway. In recent developments, Purple Biotech established a Scientific Advisory Board for its CAPTN-3 platform in April 2026 and announced an AI collaboration with Converge Bio in March 2026 to accelerate its tri-specific antibody platform development. The company also regained compliance with Nasdaq listing rules in March 2026. While CM24 and NT219 have shown promising results, the company has strategically pivoted its pipeline focus towards the CAPTN-3 platform, with the former programs being deprioritized pending strategic partnerships or investment.